

**1. Title of Study:**

GASTRIC Consortium

**2. Study PI/Contact:**

Sonia Kupfer, MD; Ophir Gilad, MD

**3. Contact Information for Primary Site:**

ophirg@bsd.uchicago.edu

**4. Site locations currently participating:**

- a. University of Chicago, Chicago, IL
- b. Ohio State University, Columbus, OH
- c. University of Michigan, Ann Arbor, MI
- d. University of Kansas, Kansas City, KS
- e. University of Pennsylvania, Philadelphia, PA
- f. Fox Chase Cancer Center, Philadelphia, PA
- g. University of Pittsburgh, Pittsburgh, PA
- h. Yale University, New Haven, CT
- i. Columbia University, New York, NY
- j. University of California San Francisco, San Francisco, CA
- k. University of Colorado, Aurora, CO
- l. Sinai Health, Toronto, Canada
- m. Providence Swedish Cancer Institute, Seattle, WA

**5. Study Identifier (NCT registration number if available)**

N/A

**6. Study abstract or synopsis**

The Group of investigAtors STRiving toward Research In CDH1 (GASTRIC) consortium was established to address gaps in CDH1 management, by harmonizing data from multiple centers who care for this population. The consortium collects de-identified data on endoscopic and histologic findings, family history, as well as surgical and post-surgical outcomes.

## **7. Description of study include sample size, study endpoints, aims**

The consortium has currently collected data on more than 390 CDH1 carriers and their families. Data collection is retrospective at present, with plans to incorporate prospective data collection in the future. The study aims are:

- A. To identify predictors of advanced gastric cancer to improve risk stratification and inform management of CDH1 carriers
- B. To assess disease penetrance in a large, multicenter cohort study
- C. To improve post-surgical care, by characterizing long-term postoperative complications and outcomes.

## **8. Participation Criteria; Inclusion criteria, Exclusion Criteria:**

Inclusion – Pathogenic/likely pathogenic variant in CDH1.

Exclusion – no known mutation, no available data.

## **9. Criteria for potential additional site to participate:**

Sites that follow patients meeting the inclusion criteria are eligible to participate.

## **10. Publications/citations**

- A. Initial reports of the endoscopic and histologic features were presented at InSight 2024, Barcelona, and CGA-IGC Annual Meeting 2024 Philadelphia. Manuscript is under review.
- B. Penetrance analysis study presented in CGA-IGC Annual Meeting 2025, St. Louis, and accepted to InSight 2026, Singapore
- C. Post-surgical outcomes study presented in DDW 2025, San Diego, and CGA-IGC Annual Meeting 2025 St. Louis.

## **11. Study Website If Available**

N/A

## **12. Potential authorship opportunity criteria**

All participating sites that contribute data will be eligible for co-authorship on resulting publications. The number of authors per site and authorship position will be determined by the magnitude of contribution, including the number of patients contributed as well as involvement in data analysis and manuscript preparation.